Cancer cells excel at evading detection, but subtle chemical differences set them apart from healthy cells. Now, a team of ...

Researchers at NYU Langone Health propose a model that could explain how cancer cells adapt to environmental stress, an ...

CRISPR Therapeutics (NASDAQ: CRSP) is a pioneering biotech company, but it isn't yet a profitable one. That's why its shares ...

Researchers at NYU Langone Health propose a model that could explain how cancer cells adapt to environmental stress, an approach that may lead to new ...

A long-standing mystery in cancer treatment is how tumor cells so often become resistant to drugs, even ones they have never encountered before.

Crispr Therapeutics AG looks set for 2026 revenue inflection as Casgevy ramps; strong efficacy, undervalued shares, robust ...

A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential ...

This important paper substantially advances our understanding of how Molidustat may work, beyond its canonical role, by identifying its therapeutic targets in cancer. This study presents a compelling ...

The global cell therapy technologies market is set to grow from USD 4.41 billion in 2025 to USD 7.91 billion by 2030, achieving a CAGR of 12.4%. Key growth drivers include advancements in regenerative ...

AI-guided genomic tools helped design experimental cancer treatment for a dog, showing collaborative future medicine ...

Trace the timeline of CRISPR-Cas9 from its 2012 discovery to the latest AI-driven advancements and "N-of-1" clinical therapies.